"Galectin 3" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A multifunctional galactin initially discovered as a macrophage antigen that binds to IMMUNOGLOBULIN E, and as 29-35-kDa lectin that binds LAMININ. It is involved in a variety of biological events including interactions with galactose-containing glycoconjugates, cell proliferation, CELL DIFFERENTIATION, and APOPTOSIS.
Descriptor ID |
D037502
|
MeSH Number(s) |
D12.776.503.307.300
|
Concept/Terms |
Galectin 3- Galectin 3
- CBP-30
- CBP-35
- CBP35
- Epsilon-Binding Protein
- Epsilon Binding Protein
- Galectin-3
- HL-29
- IgE Binding Protein
- Binding Protein, IgE
- Protein, IgE Binding
- IgEBP
- L-29 Lectin
- L 29 Lectin
- L-31
- L-34
- L30 Lectin
- LGALS3
- Mac-2 Antigen
- Antigen, Mac-2
- Mac 2 Antigen
- Macrophage-2 Antigen
- Antigen, Macrophage-2
- Macrophage 2 Antigen
- Carbohydrate-Binding Protein 35
- Carbohydrate Binding Protein 35
|
Below are MeSH descriptors whose meaning is more general than "Galectin 3".
Below are MeSH descriptors whose meaning is more specific than "Galectin 3".
This graph shows the total number of publications written about "Galectin 3" by people in this website by year, and whether "Galectin 3" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 0 | 1 | 1 |
1995 | 0 | 1 | 1 |
1997 | 0 | 1 | 1 |
1998 | 0 | 2 | 2 |
1999 | 0 | 1 | 1 |
2000 | 0 | 1 | 1 |
2001 | 0 | 2 | 2 |
2002 | 1 | 0 | 1 |
2004 | 1 | 0 | 1 |
2005 | 1 | 0 | 1 |
2006 | 1 | 0 | 1 |
2009 | 1 | 0 | 1 |
2011 | 1 | 0 | 1 |
2012 | 1 | 0 | 1 |
2013 | 1 | 0 | 1 |
2015 | 1 | 0 | 1 |
2016 | 0 | 1 | 1 |
2018 | 1 | 0 | 1 |
2021 | 0 | 1 | 1 |
2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Galectin 3" by people in Profiles.
-
Vares-Lum DL, Gangcuangco LMA, Park J, Manzano E, Ortega M, Chow DC, Shikuma C. Plasma galectin-3 is associated with decreased glomerular filtration rate in chronic HIV. HIV Res Clin Pract. 2023 09 20; 24(1):2261753.
-
Chou WC, Tsai KL, Hsieh PL, Wu CH, Jou IM, Tu YK, Ma CH. Galectin-3 facilitates inflammation and apoptosis in chondrocytes through upregulation of the TLR-4-mediated oxidative stress pathway in TC28a2 human chondrocyte cells. Environ Toxicol. 2022 Mar; 37(3):478-488.
-
Nguyen MN, Su Y, Vizi D, Fang L, Ellims AH, Zhao WB, Kiriazis H, Gao XM, Sadoshima J, Taylor AJ, McMullen JR, Dart AM, Kaye DM, Du XJ. Mechanisms responsible for increased circulating levels of galectin-3 in cardiomyopathy and heart failure. Sci Rep. 2018 05 29; 8(1):8213.
-
Liu M, Hassana S, Stiles JK. Heme-mediated apoptosis and fusion damage in BeWo trophoblast cells. Sci Rep. 2016 10 31; 6:36193.
-
Darrow AL, Shohet RV. Galectin-3 deficiency exacerbates hyperglycemia and the endothelial response to diabetes. Cardiovasc Diabetol. 2015 Jun 06; 14:73.
-
Mishra BB, Li Q, Steichen AL, Binstock BJ, Metzger DW, Teale JM, Sharma J. Galectin-3 functions as an alarmin: pathogenic role for sepsis development in murine respiratory tularemia. PLoS One. 2013; 8(3):e59616.
-
Wu KL, Huang EY, Jhu EW, Huang YH, Su WH, Chuang PC, Yang KD. Overexpression of galectin-3 enhances migration of colon cancer cells related to activation of the K-Ras-Raf-Erk1/2 pathway. J Gastroenterol. 2013 Mar; 48(3):350-9.
-
Darrow AL, Shohet RV, Maresh JG. Transcriptional analysis of the endothelial response to diabetes reveals a role for galectin-3. Physiol Genomics. 2011 Oct 20; 43(20):1144-52.
-
Alcendor DJ, Knobel SM, Desai P, Zhu WQ, Vigil HE, Hayward GS. KSHV downregulation of galectin-3 in Kaposi's sarcoma. Glycobiology. 2010 May; 20(5):521-32.
-
Baptiste TA, James A, Saria M, Ochieng J. Mechano-transduction mediated secretion and uptake of galectin-3 in breast carcinoma cells: implications in the extracellular functions of the lectin. Exp Cell Res. 2007 Feb 15; 313(4):652-64.